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Genetic testingAlmost exactly 20 years after their discovery, the BRCA1 and BRCA2 genes have become the target of the ﬁrst
“personalized” therapy available for patients with ovarian cancer. In December 2014, a poly(ADP-ribose)
polymerase (PARP) inhibitorwas granted expedited approved by theUnited States Food andDrugAdministration
for use in advanced ovarian cancer patients with germline BRCA1/2mutations who have received three or more
prior lines of chemotherapy. This review article will discuss (1) the BRCA1 and BRCA2 genes within the larger
context of homologous recombination deﬁciency; (2) the advances in our understanding of hereditary cancer
risk and the dramatic shifts that have occurred in the genetic testing landscape since the landmark 2013 Supreme
Court ruling invalidating patents on BRCA1 and BRCA2 genetic testing; and (3) the clinical trials leading to the
approval of olaparib, the ﬁrst in human PARP inhibitor.
© 2015 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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Fig. 1. A timeline of the last two decades: BRCA1/2, homologous recombination, hereditary cancer risk and approval of a targeted therapy for BRCA1/2-associated ovarian cancer.
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In the two decades since the discovery of the BRCA1 and BRCA2
genes in 1994 and 1995 [1,2], the DNA repair pathway within which
they work, homologous recombination has become a target for cancer
therapy (Fig. 1). In 2005, a decade after the discovery of the BRCA
genes, preclinical studies demonstrated that PARP inhibitors selectively
target BRCA-deﬁcient cells. Clinical trials of olaparib, the ﬁrst in human
PARP inhibitor, were launched and results for phase 1 and phase 2
studies were reported in 2009 and 2010. Despite promising data,
AstraZeneca halted development of olaparib in 2011 but then
reversed their decision in 2013 with the launch of phase 3 trials.
In December 2014, roughly 20 years after the discovery of BRCA1,
olaparib was granted accelerated approval by the United States
Food and Drug Administration (FDA) as a therapy for ovarian cancer
patients with germline BRCA1/2 mutations who have received three
or more prior lines of chemotherapy.
In the past year, the genetic testing landscape for BRCA1 and BRCA2
mutations shifted dramatically. In a 2013 landmark ruling, the Supreme
Court of the United States invalidated the patents that gave Myriad
Genetics the exclusive rights to BRCA1 and BRCA2 genetic testing.
Many companies now offer BRCA1 and BRCA2 genetic testing within
larger gene panels that include other genes in the homologous recombi-
nation pathway as well as other hereditary cancer genes. Alongside
the olaparib approval in December 2014, the FDA also approved the
BRACAnalysis CDx™ test by Myriad Genetics as the companion
diagnostic test to identify candidates for olaparib treatment.
Homologous recombination and hereditary cancer risk
BRCA1 and BRCA2 are critical proteins in the process of homologous
recombination repair of double-strand DNA breaks. Germline BRCA1
and BRCA2mutations account for about 5 – 10% of breast cancers andTable 1
Homologous recombination genes linked to hereditary breast and ovarian cancer
susceptibility.
Gene Hereditary breast cancer risk Hereditary ovarian cancer risk
CHEK2 Am J Hum Genet 2004 Walsh, PNAS 2011
BRIP1 Seal, Nat Genet 2006 Rafnar, Nat Genet 2011
ATM Renwick, Nat Genet 2006 Walsh, PNAS 2011
NBN Steffen, Int J Ca 2006 Walsh, PNAS 2011
PALB2 Rahman, Nat Genet 2007 Walsh, PNAS 2011
RAD51C Meindl, Nat Genet 2007 Meindl, Nat Genet 2010
BARD1 De Brakeleer, Hum Mutat 2010 Walsh, PNAS 2011
MRE11A Damiola, Breast Ca Res 2014 Walsh, PNAS 2011
RAD50 Damiola, Breast Ca Res 2014 Walsh, PNAS 2011
RAD51D n/a Loveday, Nat Genet 201110 – 18% of ovarian cancers [3]. Many of the other proteins involved in
homologous recombination repair are now recognized to also contrib-
ute to hereditary cancer risk including ATM, CHEK2, BARD1, BRIP1,
Mre11, RAD50, NBS1, RAD51C, RAD51D and PALB2. Table 1 summarizes
the studies implicating homologous recombination genes in breast and
ovarian cancer susceptibility. Many of these genes were ﬁrst connected
to breast cancer susceptibility [4–11], andmore recently, BRIP1, RAD51C
and RAD51D were linked to hereditary ovarian cancer risk [9,12,13].
A study utilizing next-generation sequencing on the normal DNA of
unselected ovarian cancer patients found deleterious germline
mutations in BARD1, BRIP1, CHEK, MRE11A, MSH6, NBN, PALB2,
RAD50, RAD51C and TP53 and estimated these mutations to account
for approximately 6% of hereditary ovarian cancer risk [14]. Of note,
30% of patients with a homologous recombination gene mutation in
this study had no family history of breast or ovarian cancer. An impor-
tant caveat to this data is the lack of comparable germline mutation
rates in the general unaffected population.
These genes implicated in hereditary breast and ovarian cancer
susceptibility have important roles in the homologous recombination
DNA repair process (Fig. 2). The steps in homologous recombination re-
pair have been reviewed in other articles [15–17] and are schematically
described here. In the initial stages of homologous recombination,
a double-strand DNA break is recognized by ATM and ATR, kinases
which phosphorylate downstream targets including CHEK2, P53,
BRCA1 and H2AX. BRCA1, assisted by BARD1 and BRIP1, acts as a
scaffold that organizes the remaining proteins to the site of repair. The
MRN complex, which consists of MRE11, RAD50 and NBS1, then resects
theDNA to form3′ overhangs that are bound by RPA. BRCA2 is recruited
with the assistance of PALB2 and loads RAD51 onto RPA-coated
DNA with the assistance of RAD51B, RAD51C and RAD51D. The RAD51
nucleoprotein ﬁlament then invades the homologous DNA strand in a
process called strand invasion, allowing the remaining DNA repair to
occur with the use of the sister chromatid as a template for error-free
repair [15–17]. In Fig. 2, BRCA1 and BRCA2 are indicated in red and
the other homologous recombination genes/proteins implicated in
genetic breast and ovarian cancer susceptibility are indicated in orange.
The BRCA phenotype in serous ovarian cancers
The Cancer Genome Atlas (TCGA) suggests that up to half of high-
grade serous ovarian cancers could be deﬁcient in homologous
recombination [18]. Deﬁciency of either BRCA1 or BRCA2 occurs
through germline mutation (9% BRCA1, 8% BRCA2), somatic mutation
(3% BRCA1 or BRCA2) or through epigenetic silencing of BRCA1 (11%).
Other genetic changes impacting homologous recombination repair
include ampliﬁcation of EMSY (8%), deletion/mutation of PTEN (7%),
hypermethylation of RAD51C (3%), mutation of ATM or ATR (2%) or mu-
tation of other homologous recombination genes (5%). These tumors
ATM ATR Kinases recognize double -strand DNA break
CHEK2 P53 BRCA1 H2AX Phosphorylated
BRCA1 acts as scaffold, organizes repair proteins
BARD1 BRIP1 Interact with BRCA1
Mre11 RAD50 NBS1 MRN complex resects DNA
RPA Binds 3’ overhangs of single -stranded DNA
BRCA2 Loads onto RPA-coated DNA
RAD51B RAD51C RAD51D
RAD51
PALB2
A. Double-strand DNA break – recognition and assembly of repair proteins
B. End Resection
C. RAD51 loading
D. Strand Invasion – RAD51 nucleoprotein filament invades homologous DNA
E. DNA Synthesis and Repair
Fig. 2. Proteins implicated in hereditary breast and ovarian cancer risk and their role in homologous recombination repair. The protein products of genes implicated in hereditary breast
and ovarian cancer susceptibility are indicated in red (BRCA1 and BRCA2) and orange (other homologous recombination genesmore recently linked to cancer risk). A. Double-strandDNA
break—recognition and assembly of repair proteins. Homologous recombination repair of double-strand DNA breaks is initiated by recognition by ATM and ATR which phosphorylate
downstream targets including CHEK2, P53, BRCA1, and H2AX. BRCA1, assisted by BARD1 and BRIP1, acts as a scaffold to organize the assembly of other repair proteins. B. End resection.
The MRN complex, consisting of MRE11, RAD50 and NBS1, resects DNA. C. RAD51 loading. RPA binds the 3′ overhangs of single-stranded DNA. BRCA2 is recruited with the help of PALB2
and loads RAD51 onto the RPA-coated DNA with the assistance of RAD51B, RAD51C, and RAD51D. D. Strand invasion. The RAD51 nucleoprotein ﬁlament invades the homologous DNA
stand through strand invasion. E. DNA synthesis and repair. The homologous DNA strand provides a template for high-ﬁdelity and error-free DNA synthesis and repair.
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behave like BRCA-deﬁcient tumors despite normal germline BRCA1 and
BRCA2 genes [19].
The rapidly evolving genetic testing landscape
BRCA1was identiﬁed in 1994 and BRCA2was identiﬁed in 1995 [1,2].
Since patents were granted in 1997 and 1998, Myriad Genetics has held
the exclusive license rights for BRCA1 and BRCA2 genetic testing in the
United States. These rights were enforced against other clinical diagnostic
labs, leading to a monopoly and high testing costs for many years.
In 2009, the Association for Molecular Pathology v. Myriad Genetics
lawsuit was ﬁled by the American Civil Liberties Union and the
Public Patent Foundation on behalf of universities, medical organiza-
tions, patient advocacy groups and patients who alleged that genes
are a product of nature, making Myriad's patent claims are invalid.
On March 29, 2010, the Southern District Court of New York agreed,
ruling that all challenged claims were ineligible for patent. Myriad
Genetics appealed to the Federal Circuit Appeals Court who
overturned the lower court decision on July 29, 2011. This led to
an appeal to the United States Supreme Court who unanimously
ruled against Myriad Genetics in a landmark ruling delivered on
June 13, 2013.Almost immediately after the Supreme Court decision in June 2013,
other clinical diagnostic laboratories started to offer BRCA1 and BRCA2
testing, both in isolation as well as part of more comprehensive genetic
susceptibility panels. Myriad ﬁled lawsuits against competing compa-
nies, including Ambry, Gene by Gene and Pathway Genomics, citing
infringement on the remaining patents that were not impacted by the
Supreme Court decision. InMarch 2014, a federal judge deniedMyriad's
request of injunction, a pre-trial order for competitors to cease BRCA1/2
testing for the duration of the case. In December 2014, the Court of
Appeals for the Federal Circuit ruled that Myriad's patents are invalid.
Also in December 2014, the Myriad BRACAnalysis CDx™ test was
approved by the United States Food and Drug Administration as the
companion diagnostic test to olaparib use in ovarian cancer patients.
In January 2015, Myriad dropped its remaining patent disputes and
has settled or is in talks with its competitors.
BRCA1 and BRCA2 genetic testing is now available through a number
of companies including (not a comprehensive list) Ambry Genetics,
Counsyl, Gene by Gene, GeneDx, Invitae, Laboratory Corporation
of America, Myriad Genetics, Pathway Genomics, Quest Diagnostics
and the University of Washington (Table 2). Many companies offer
BRCA1/2 genetic testing within the context of larger gene panels,
ranging from 5 to 48 different genes. The panels include various
combinations of homologous recombination genes (BRCA1, BRCA2,
Table 2
Commercially available BRCA1/2 genetic tests and hereditary cancer risk panels.
Company BRCA1/2 tests Panel (number of
genes)
Ambry Genetics BRCA1/2 sequencing and deletion/duplication
BRCA1/2 deletion/duplication
BRCA single site analysis
BRCAplus (5)
GYNplus (9)
BreastNext (17)
CancerNext (28)
OvaNext (23)
PancNext (13)
Counsyl BRCA1 and BRCA2 screen N/A
Gene by Gene BRCA1 (only available outside North America)
BRCA2 (only available outside North America)
N/A
GeneDx BRCA1/2 Del/Dup
BRCA1/2 sequencing
BRCA1/2 Ashkenazi Founder Mutation Panel
BRCA1/2 sequencing and Del/Dup analysis
High/Moderate Risk Panel (20)
Breast/Ovarian Cancer Panel (21)
OncoGeneDx Custom Panel (28)
Comprehensive Cancer Panel (29)
Invitae BRCA1 and BRCA2 Hereditary breast cancer, moderate-risk panel (5)
Hereditary breast cancer, high-risk panel (7)
Hereditary breast cancer, extended panel (12)
Hereditary pancreatic cancer (17)
Women's hereditary cancers (17)
Hereditary cancer syndromes (29)
Laboratory Corporation of AmericaLabCorp BRCAssure—BRCA1/2 comprehensive analysis
BRCAssure—BRCA1/2 duplication/deletion analysis
BRCA1 targeted analysis
BRCA2 targeted analysis
BRCA1/2 Ashkenazi Jewish Proﬁle
N/A
Myriad Genetics BRACAnaylsis CDx My Risk (25)
Pathway Genomics BRCATrue
BRCATrue Ashkenazi Jewish (3-site)
BreastTrue High Risk Panel (7)
Quest Diagnostics BRCAvantage, rearrangements
BRCAvantage, comprehensive
BRCAvantage, Ashkenazi Jewish Screen
BRCAvantage, Ashkenazi Jewish Screen with reﬂex to comprehensive
BRCAvantage, single site
BRCAvantage with reﬂex to BRCAvantage Plus panel
BRCAvantage Plus (7)
University of Washington BRCA1
BRCA2
BRCAAJ—Ashkenazi Jewish panel
BROCA (48)
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RAD51D, XRCC2) as well as other cancer susceptibility genes (CDH1,
TP53, STK11, PTEN, APC, AXIN2, BMPR1A, CDK4, CDKN2A, EPCAM,
FANCC, MLH1, MSH2, MSH6, MUTYH, NF1, PMS, SMAD4, VHL). The
BROCA panel offered by the University of Washington also contains
genes that are not included in other commercially available panels
(AKT1, ATR, BAP1, CHEK1, CTNNA1, FAM175A, GALNT12, GEN1,
GREM1, HOXB13, PIK3CA, POLD1, POLE, PRSS1, RAD51, RET, SDHB,
SCHC, SCHD, TP53BP1). For many of these genes, the magnitude of
cancer risk associated with a deleterious mutation has not been
clearly deﬁned. Panel testing offers a more comprehensive picture
of hereditary cancer risk, but clinical practice guidelines do not
always exist to guide decision making.
Targeting homologous recombination
The phenotype of BRCA-deﬁcient ovarian cancers is of enhanced
survival [20–23], largely attributed to a better response to platinum
chemotherapy. This phenotype of enhanced survival appears to also
extend to ovarian cancers with deﬁciencies in other homologous
recombination genes [24]. Reversion mutations in the BRCA1/2 genes
can restore the coding frame and allow for the expression of functional
BRCA protein, reversing the survival beneﬁt by conferring resistance to
platinum [25,26]. BRCA1/2-deﬁcient breast and ovarian cancers also
appear to have an enhanced response to doxorubicin and pegylated
liposomal doxorubicin [27,28].
BRCA1/2-deﬁcient cancers are now recognized as the target for
a class of drugs known as PARP (poly(ADP-ribose) polymerase) inhibi-
tors. PARP inhibitors are thought to work through direct blockingof PARP enzymatic activity as well as through PARP accumulation
on DNA in a process called PARP trapping [29,30]. PARP inhibitors
induce synthetic lethality in BRCA-deﬁcient tissues. Deﬁciency of PARP
or BRCA alone has no impact, but a deﬁciency in both leads to a lethal
effect (Fig. 3).
PARP represents a family of enzymes involved in base excision
repair, a key pathway in the repair of single-strand DNA breaks
(Fig. 3A). When PARP is inhibited, single strand DNA breaks are con-
verted into double-strand DNA breaks through collapse of the repli-
cation fork (Fig. 3B). A double-strand DNA break can be repaired by
one of two different pathways: homologous recombination or non-
homologous end joining (NHEJ). Homologous recombination occurs
in the G2 orM phase of the cell cycle when a sister chromatid is avail-
able to use as a template for repair. Because a template is available,
homologous recombination is a high ﬁdelity, error-free form of
DNA repair. In contrast, NHEJ does not utilize a template. The DNA
is simply trimmed and ligated and this error-pronemechanism of re-
pair can lead to genetic instability [15]. In BRCA-deﬁcient tumors,
homologous recombination is not functional, and the cell is directed
towards error-prone repair and cell death.
The absence of either a functioning homologous recombination
(HR) or base excision repair (BER) pathway has no detrimental
impact on cell viability, but the deﬁciency of both together leads to
synthetically lethal death (Fig. 3C). Normal cells (HR+, BER+),
untreated BRCA-deﬁcient cancer cells (HR−, BER+), and normal
non-cancer cells treated with a PARP inhibitor (HR+, BER−) are
all viable conditions. However, BRCA-deﬁcient cancer cells treated
with a PARP inhibitor (HR−, BER−) are selectively targeted for a
synthetically lethal cell death.
A.
B.
C.
Fig. 3.PARP inhibitors induce synthetic lethality in BRCAdeﬁcient cells. A. In thepresence of functioning PARP enzyme, single-strandDNAbreaks are repaired. B.When the PARP enzyme is
inhibited, single-strand DNA breaks are converted into a double-strand DNA break through collapse of the replication fork. In BRCA-deﬁcient tumor cells, homologous recombination
repair of double-strand DNA breaks is impaired and cells are directed towards the error-prone repair process of non-homologous end joining which leads to genetic instability and cell
death. C. Cells deﬁcient in either homologous recombination (HR) or base excision repair (BER) maintain viability, while cells deﬁcient in both through BRCA deﬁciency and PARP
inhibition undergo synthetically lethal cell death.
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the observation that loss of PARP1 function induces the formation of
nuclear RAD51 foci, a marker of active double-strand DNA break repair
[31]. This led to the hypothesis that inhibition of PARP in BRCA-deﬁcient
cells would cause accumulation of DNA lesions that would not be ade-
quately repaired. In 2005, compelling pre-clinical data demonstrated
that BRCA-deﬁcient cells are 1000-times more sensitive to PARP
inhibitors than wild type cells [32,33].
Clinical development of PARP inhibitors
Olaparib—phase 1
Following the compelling preclinical data demonstrating selective
targeting of BRCA-deﬁcient cells by PARP inhibitors, a phase 1 clinical
trial was rapidly initiated to test olaparib, theﬁrst in human PARP inhib-
itor. The trial recruited patients with refractory solid tumors and was
enriched for BRCA1 and BRCA2 germline mutation-carriers (22 of the
60 patients) [34]. A supplemental secondary cohort of 50 additionalBRCA1/2 mutation carriers was subsequently recruited [35]. A maxi-
mum tolerated dose of oral olaparib 400 mg twice daily was identiﬁed
through dose escalation. The drug was well tolerated causing mainly
mild fatigue and gastrointestinal toxicities and toxicities did not
differ based on germline BRCA1/2 mutation status of the patients.
Pharmacokinetic studies demonstrated PARP inhibition to be occurring
in peripheral tissues [34].
Responses appeared to be limited to germline BRCA1/2 mutation
carriers in this phase 1 trial. Clinical beneﬁt, deﬁned as complete
response + partial response + stable disease, was seen in 63% (12 of
19) BRCA1/2 mutation carriers. Among the 9 patients with partial
responses, 8 had ovarian cancer. When looking at the overall patient
population of 60 patients, 16 (27%) had a response. There were no
responses in any sporadic ovarian cancers [34].
In the secondary cohort of BRCA1/2mutation carriers, PARP response
correlated with platinum sensitivity with 69% of platinum sensitive pa-
tients responding to PARP inhibitors compared to 45% of platinum
resistant and 23% of platinum refractory patients [35]. The major
348 C.S. Walsh / Gynecologic Oncology 137 (2015) 343–350conclusions of this trial were that responses appeared to be limited to
the BRCA1/2 mutation carriers and the clinical beneﬁt rate correlated
with platinum sensitivity [34,35].
Olaparib—phase 2
The phase 1 ﬁndings led to a series of phase 2 proof-of-concept trials
published in 2010 conﬁrming the efﬁcacy and tolerability of olaparib in
patients with BRCA1/2-associated advanced ovarian and breast cancer
[36,37]. Both trials demonstrated higher response rates at the higher
dose of oral olaparib 400 mg twice daily than at the lower dose of
100 mg twice daily. At the higher dose, 33% of ovarian cancer patients
[36] and 41% of breast cancer patients [37] responded to treatment.
Another phase 2 trial published in 2011was the ﬁrst to demonstrate
activity of olaparib in sporadic ovarian cancers [38]. In addition to
recruitingpatientswith germlineBRCA1/2 associated ovarian and breast
cancer, the trial also included patients with sporadic high grade serous
ovarian cancer and sporadic triple negative breast cancer. All patients
were treated with the higher dose of olaparib 400 mg twice daily. This
trial conﬁrmed a 41% response rate in BRCA1/2 mutation carriers with
ovarian cancer, but in contrast to the phase 1 trial ﬁndings, 24% of
patients with sporadic ovarian cancer also responded to PARP inhibitor
treatment. Platinum sensitivity correlated with response to PARP
inhibition in both subsets of patients. Among patients with platinum
sensitive ovarian cancers, 60% of germline BRCA1/2 mutation carriers
and 50% of patients with sporadic tumors responded. Among platinum-
resistant patients, 33% of germline BRCA1/2 and 4% of sporadic patients
responded. There were no responses in any patients with triple-
negative breast cancer. The demonstration of activity in sporadic
ovarian cancer suggests a possible expansion of the patient population
that might beneﬁt from these drugs. The trial also suggested that plati-
num sensitivity is a surrogate marker for homologous recombination
deﬁciency [38].
Another phase 2 trial published in 2012 tested the hypothesis
that olaparib would be more effective than standard of care,
deﬁned as pegylated liposomal doxorubicin, in platinum-resistant
BRCA1/2-mutated ovarian cancer with a progression-free interval of
less than 12 months [39]. The trial demonstrated no difference in
response rates between patients treated with olaparib 200 mg twice
daily (25% response), olaparib 400 mg twice daily (31% response) or
pegylated liposomal doxorubicin (PLD) 50 mg/m2 (18% response).
Patients treated at the lower and higher doses of olaparib had
progression-free survival (PFS) times of 6.5 months and 8.8 months
respectively, which was no different than the PFS of 7.1 months
among patients treated with PLD. However, the 7.1 month PFS in theTable 3
Ongoing phase 3 PARP inhibitor trials in ovarian cancer.
Trial Patients Eligibility
NCT01844986
SOLO 1
AstraZeneca
344 ovary
All BRCA1/2+
Maintenance after new diagnos
or endometrioid, after platinum
NCT01874353
SOLO 2
AstraZeneca
264 ovary
All BRCA1/2+
Maintenance after recurrence, p
NCT02282020
SOLO 3
AstraZeneca
411 ovary
All BRCA1/2+
Platinum sensitive relapsed ova
olaparib vs. physicians choice o
PLD or gemcitabine
NCT01968213
ARIEL 3
Clovis Oncology
540 ovary
BRCA1/2+ and sporadic
Maintenance after recurrence, p
NCT01847274
NOVA
Tesaro
360 ovary
BRCA1/2+ and sporadic
Maintenance after recurrence, pchemotherapy arm was greater than expected compared to historical
controls of about 4 months, leading the authors to suggest that this
patient population with germline BRCA1/2 mutations may indeed be
more sensitive to this type of drug. The authors also commented that
there were twice as many grade 3 toxicities in the patients receiving
PLD and that PARP inhibitors might be a reasonable alternative with a
better toxicity proﬁle in this patient population [39].
Olaparib—maintenance therapy
To test the impact of olaparib as maintenance therapy in an ovarian
cancer patient population in remission, a randomized, double-blind,
placebo-controlled, phase 2 trial was conducted [40]. This trial enrolled
patients with high-grade serous ovarian cancer with or without a
germline BRCA1 or BRCA2 mutation who had previously received at
least 2 prior lines of platinum-based chemotherapy and had a partial
or complete response to their most recent platinum-based chemother-
apy regimen. Patients receiving oral olaparib 400 mg twice daily had a
longer PFS of 8.4 months compared to 4.8 months in patients taking
placebo. These data were presented at the American Society of Clinical
Oncology (ASCO) Annual Meeting in 2011 and subsequently published
in 2012 [40]. In late 2011, however, AstraZeneca announced that they
would not continue development of olaparib for serous ovarian cancer
because the beneﬁt in PFS was not projected to translate into an
improvement in overall survival (OS).
Fortunately, AstraZeneca reversed this decision in 2013 after a
retrospective analysis of the phase 2 data was presented at the
2013 ACSO Annual Meeting (subsequently published in 2014) [41].
A preplanned analysis of the data was presented based on BRCA1/2
mutation status. Among 131 patients receiving olaparib and 123
patients receiving placebo, 56% and 50% of patients had a deleterious
or suspected deleterious mutation in BRCA1 or BRCA2. The sub-
analysis demonstrated the greatest beneﬁt to germline BRCA1/2
mutation carriers with a difference in PFS of 11.2 months compared
to 4.3 months in patients receiving olaparib versus placebo (hazard
ratio 0.18, 95% conﬁdence interval 0.10, 0.31, p b 0.0001). Patients
with sporadic ovarian cancer had a more modest improvement
in PFS of 7.4 months versus 5.5 months (hazard ratio 0.54, 95%
conﬁdence interval 0.34, 0.85, p = 0.0075). There was no difference
in OS in either subgroup [41].
The SOLO1 and SOLO2 phase 3 trials were initiated in June 2013 to
investigate the use of olaparib in treatment and maintenance for
patients with advanced ovarian cancer after new diagnosis (SOLO1)
and after platinum-sensitive recurrence (SOLO2) (Table 3). Both trials
were designed with PFS as the primary endpoint with the hopes that a
large PFS beneﬁt would be sufﬁcient for regulatory approval.Treatment arms
is, advanced stage high grade serous
treatment
1. Olaparib
2. Placebo
latinum-sensitive 1. Olaparib
2. Placebo
rian cancer, ≥2 prior lines chemotherapy,
f weekly paclitaxel, topotecan,
1. Olaparib
2. Physician's choice chemotherapy
latinum-sensitive 1. Rucaparib
2. Placebo
latinum-sensitive 1. Niraparib
2. Placebo
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maintenance therapy
Shortly thereafter, there was considerable enthusiasm that
olaparib could be granted accelerated approval by the FDA. However,
in June 2014, the Oncologic Drugs Advisory Committee (ODAC)
reviewed the data on use of olaparib as monotherapy for maintenance
treatment in patients with BRCA1/2-associated platinum-sensitive
relapsed ovarian cancer. Citing safety concerns with the risks of
myelosuppression, fatigue, nausea, abdominal pain and the small but
concerning risk for myelodysplatic syndrome and acute myelogenous
leukemia, ODAC voted 11 to 2 against accelerated approval for this
indication and recommended waiting for the conﬁrmatory results of
the SOLO2 trial [42].
Olaparib monotherapy in germline BRCA1/2-associated advanced cancers
In a study presented at ASCO in 2013 and published in November
2014, the efﬁcacy and safety of single agent oral olaparibwere evaluated
in a spectrum of germline BRCA1/2-associated cancers, including
platinum-resistant ovarian cancer, heavily pretreated breast cancer,
pancreatic cancer previously treated with gemcitabine and prostate
cancer with progression on hormonal or systemic therapy. Therapeutic
responses were seen in a broad range of tumors [43]. Among 193
patients with platinum-resistant ovarian cancer, 31.1% responded,
40% had stable disease greater than 8 weeks, 21% progressed and the
median PFS andOSwere 7months and 16.6months. Among62patients
with heavily pretreated breast cancer, 12.9% responded, 47% had stable
disease, 37% progressed and the median PFS and OS were 3.7 months
and 11 months. Among 23 patients with pancreatic cancer, 21.7%
responded, 35% had stable disease, 39% progressed and the median
PFS and OS were 4.6 months and 9.8 months. Among 8 patients with
prostate cancer, 50% responded, 25% had stable disease, 25% progressed
and the median PFS and OS were 7.2 months and 18.4 months. These
data suggest activity of single-agent olaparib in a broad range of
BRCA1/2-associated cancers, irrespective of anatomic origin [43].
Olaparib receives FDA approval for treatment of BRCA-mutated advanced
ovarian cancer
After the ODAC vote against accelerated approval for olaparib as
a maintenance therapy in ovarian cancer, AstraZeneca submitted
additional information to the FDA to support the use of olaparib in
treatment of patients with BRCA1/2-associated advanced ovarian cancer
who have received three or more prior lines of chemotherapy. Among
137 such heavily pretreated patients receiving oral olaparib 400 mg
twice daily, 34% had objective responses that lasted an average of
7.9 months. Based on this data, on December 19, 2014, the FDA
granted accelerated approval for olaparib to be used for this indica-
tion. The approval is contingent upon results of the ongoing SOLO3
clinical trial (Table 3). In this trial, ovarian cancer patients with
BRCA1/2-associated relapsed platinum-sensitive ovarian cancer
who have received two or more prior lines of chemotherapy will be
randomized to olaparib versus physician's choice of single-agent
chemotherapy (weekly paclitaxel, topotecan, pegylated liposomal
doxorubicin or gemcitabine). The primary outcome measure is
progression free survival.
Ongoing clinical trials evaluating PARP inhibitors in ovarian cancer
In addition to the SOLO trials studying olaparib, two additional PARP
inhibitors, rucaparib (Clovis Oncology) and niraparib (Tesaro) are
currently being evaluated in Phase 3 trials of maintenance treatment
after platinum-sensitive recurrent ovarian cancer (Table 3). In contrast
to the SOLO trials which are exclusively recruiting patients with
germline BRCA1/2 mutations, the ARIEL 3 (studying rucaparib) and
NOVA (studying niraparib) trials are recruiting both sporadic and
BRCA1/2 ovarian cancer patients. Veliparib (AbbVie) has been evaluated
as a single-agent treatment in BRCA1/2+ persistent or recurrentovarian cancer in theGOG 280 phase 2 trial presented at the 2014 annu-
al Society of Gynecologic Oncology meeting [44]. The overall response
rate of 26% was thought to support investigation of veliparib in a
phase 3 trial. Iniparib (BiPar, Sanoﬁ-Aventis) is no longer considered a
PARP inhibitor [45]. BMN-673 (BioMarin) is not speciﬁcally being tested
in ovarian cancer at this time.
Conclusions
Since the discovery of the BRCA1 and BRCA2 genes two decades ago,
signiﬁcant advances have been made that make the homologous
recombination DNA repair pathway a predictive and therapeutic target
in oncology. BRCA1 and BRCA2 are critical members of homologous
recombination DNA repair, which utilizes the sister chromatid
(homologous chromosome) as a repair template to promote high-
ﬁdelity, error-free repair of double-stranded DNA breaks. Individuals
with a germline mutation in BRCA1 or BRCA2 have a heightened risk
of developing breast, ovarian and other cancers. In these individuals,
cancer cells have lost normal BRCA1 or BRCA2 activity and have
impaired function, whereas non-tumor cells maintain a functional
copy of the BRCA1 or BRCA2 gene. This differential absence/presence
of homologous recombination activity in cancer and non-cancer cells
has led to the ability to selectively target BRCA-deﬁcient cancer cells
with an emerging class of compounds called PARP inhibitors. PARP is
involved in base excision repair, the key pathway to repair single-
strand DNA breaks. With PARP inhibition, single-strand DNA breaks
are converted into double-strand DNA breaks which cannot be
repaired in BRCA-deﬁcient cancer cells. Thus, PARP inhibitors work
though the concept of synthetic lethality, where deﬁciency of either
PARP or BRCA alone has no impact on cell viability, but the loss of
both results in a lethal effect. PARP inhibitors have been in clinical
development since 2005, when compelling pre-clinical data demon-
strated BRCA-deﬁcient cells to be orders of magnitude more sensi-
tive to PARP inhibitors than wild type cells. In December 2014, two
decades after the discovery of the BRCA1/2 genes, olaparib, the ﬁrst
in human PARP inhibitor was approved for treatment of patients
with germline BRCA1/2-associated advanced ovarian cancer who
have received three or more prior lines of chemotherapy. This ap-
proval represents the ﬁrst “personalized” therapy for ovarian cancer.
Alongside the approval of olaparib was the approval of the Myriad
Genetics BRACAnalysis CDx™ test as the companion diagnostic to
identify patients eligible for olaparib treatment.
Other genes in the homologous recombination pathway are now
recognized to contribute to hereditary cancer risk, and although the
exact magnitudes of elevated risk are not yet deﬁned, these genes are
included on multi-gene panel testing that include BRCA1 and BRCA2.
Since the 2013 ruling by the United States Supreme Court invalidating
patent rights to BRCA1 and BRCA2 genetic testing, there are numerous
companies offering testing as part of larger gene panels.
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